3型肝炎NS3/4A蛋白酶中药物耐药性的分子和动态机制
Djadé I Soumana1, Nese Kurt Yilmaz1, Akbar Ali1
1Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School , Worcester, Massachusetts 01605, United States.
Journal of the American Chemical Society
|August 12, 2016
概括
肝炎C病毒 (HCV) 蛋白酶抑制剂对基因型3的有效性较低. 这项研究揭示了蛋白质抑制剂动态的变化,而不仅仅是结构变化,解释了这种降低的功效,指导了未来的药物开发.
科学领域:
- 病毒学
- 结构生物学
- 药物发现
背景情况:
- 全球有1.5亿人感染C型肝炎病毒, 导致肝硬化和肝癌.
- 直接作用抗病毒药物 (DAA) 改变了HCV治疗,但疗效因基因型而异.
- 目前的NS3/4A蛋白酶抑制剂对HCV基因型3 (GT-3) 的有效性有所降低.
研究的目的:
- 阐明HCV NS3/4A蛋白酶抑制剂对GT-3的功效降低的分子基础.
- 了解在GT-3感染中导致PI失效的结构和动态因素.
主要方法:
- 为结晶设计了一种仿真GT-1a3a NS3/4A蛋白酶.
- 确定了与三种蛋白酶抑制剂结合的喜马拉的高分辨率晶体结构.
- 进行了分子动力学模拟和抑制测试.
主要成果:
- 在GT- 1和GT- 1a3a蛋白酶与抑制剂结合之间观察到微妙的结构差异.
- 在木乃伊中发现了结相互作用的显著变化和抑制剂的动态波动.
- 在分子间动力学损失和抑制剂功效降低之间发现了强烈的相关性.
结论:
- 减少HCV蛋白酶抑制剂对GT-3的有效性主要是由于蛋白抑制剂复合物的动态变化,而不仅仅是静态结构变化.
- 影响分子间动态的基因型多态是理解和克服PI抵抗的关键.
- 这些发现为设计针对不同基因型的更有效的HCV疗法提供了分子基础.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
57
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Pharmacogenetics of Drug Metabolism: Overview
90
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
90
Drug toxicity: Idiosyncratic Reactions
114
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
114
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
99
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
99


